203 related articles for article (PubMed ID: 37465082)
1. Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report.
Liu Z; Song P; Zhou L; Ji D; Shen H; Dong H; Feng X
Cancer Manag Res; 2023; 15():645-650. PubMed ID: 37465082
[TBL] [Abstract][Full Text] [Related]
2. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
3. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
4. Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report.
Li D; Gui Q; Xu C; Shen M; Chen K
Medicine (Baltimore); 2021 Jul; 100(30):e26375. PubMed ID: 34397683
[TBL] [Abstract][Full Text] [Related]
5. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
6. A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with
Kuang Y; Wang J; Xu P; Zheng Y; Bai L; Sun X; Li Z; Gan R; Li H; Ke Z; Tang K
Ann Transl Med; 2021 Aug; 9(16):1354. PubMed ID: 34532491
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic
Zheng W; Niu N; Zeng J; Ke X; Jin S
Transl Cancer Res; 2022 Oct; 11(10):3895-3902. PubMed ID: 36388025
[TBL] [Abstract][Full Text] [Related]
8. Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.
Takamori S; Seto T; Yamaguchi M; Kinoshita F; Fujishita T; Ito K; Toyozawa R; Shoji F; Okamoto T
Front Oncol; 2022; 12():965741. PubMed ID: 36313664
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon
Ou L; Tang Y; Deng Y; Guo L; He Q; He T; Feng W
Front Oncol; 2022; 12():911362. PubMed ID: 35957915
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
11. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
12. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with
Zhu VW; Schrock AB; Ali SM; Ou SI
Lung Cancer (Auckl); 2019; 10():21-26. PubMed ID: 30881166
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.
Gijtenbeek RGP; Damhuis RAM; van der Wekken AJ; Hendriks LEL; Groen HJM; van Geffen WH
Lancet Reg Health Eur; 2023 Apr; 27():100592. PubMed ID: 36817181
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
Shen Q; Qu J; Chen Z; Zhou J
Front Oncol; 2021; 11():760097. PubMed ID: 34926262
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
[TBL] [Abstract][Full Text] [Related]
17. Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.
Xiang S; Zeng L; Xiang M; Zhang Y
Heliyon; 2023 Nov; 9(11):e22515. PubMed ID: 38074875
[TBL] [Abstract][Full Text] [Related]
18. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
Front Oncol; 2021; 11():649766. PubMed ID: 34249687
[TBL] [Abstract][Full Text] [Related]
19. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
20. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]